Multinational cooperation for vaccine development
Accelerating the licensure of Lassa vaccines, 25-26 Oct 2022 - Abuja, Nigeria

César Muñoz-Fontela, Bernhard Nocht Institute for Tropical Medicine and WHO R&D Blueprint
Vaccine development timelines

- Lupton et al., Lancet 1980
- ERVEBO (EUA)
- Kiley et al., Lancet 1979
- Lassa??
- Laczkó et al., Immunity 2020
- Biontech COVID-19 vaccine
Global collaboration = Speed

1- Immunogen (basic science)

2- Candidate selection

3- Preclinical phase (models)

Global collaboration speeds up vaccine development by *sharing information* and avoiding *duplication* and *bottlenecks*.
Umbrella = WHO Expert working groups
Worldwide collaboration online
MARVAC Expert Working Group
WHO R&D Blueprint Coordinated consortium to promote international collaboration for the development of MVD vaccines

COVID-19 Animal Models

COVID-19 Assays

MARVAC

INDUSTRY
NON-PROFIT
ACADEMIA
GOVERNMENT
MARVAC Expert Working Group
Principles

1- Sharing of assays and reagents

2- Promoting access to laboratory networks in MDV-endemic countries

3- Promoting structural support for preclinical development of upcoming MDV vaccines
1- Strategic goals

1- To establish a platform trial design for vaccines against Marburg and Sudan virus

2- To setup a WHO-coordinated consortium including regulators, developers and members of academia to accelerate the development of filovirus vaccines (WHO-MARVAC)

3- To foster the exploration of different vaccine platforms that incorporate different targets with the goal of developing multivalent vaccines.

4- To compile data on the duration of protective immunity after vaccination with EBOV vaccines and identify the correlates of protection involved to facilitate faster evaluation of promising vaccine candidates against other filoviruses.
2- Milestones

1- By 2025, clinical evaluation for vaccine candidates against Marburg and Sudan virus.

2- By 2030, obtain licensure for at least one vaccine against Marburg virus or Sudan virus.

3- By 2030, develop a broad-spectrum filovirus vaccine that is low cost, efficacious and safe.
Thank you

For more information please contact:
César Muñoz-Fontela
munozc@who.int
@CesarMFontela

WHO Headquarters in Geneva
Avenue Appia 20
1202 Geneva
Telephone: +41-22-7912111